A detailed history of ETF Managers Group, LLC transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, ETF Managers Group, LLC holds 68,940 shares of ORMP stock, worth $164,766. This represents 0.01% of its overall portfolio holdings.

Number of Shares
68,940
Holding current value
$164,766
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

BUY
$1.93 - $13.1 $133,054 - $903,114
68,940 New
68,940 $150,000
Q3 2022

Nov 14, 2022

BUY
$4.6 - $9.91 $32,788 - $70,638
7,128 Added 8.16%
94,493 $612,000
Q2 2022

Aug 15, 2022

BUY
$3.72 - $9.0 $141,642 - $342,684
38,076 Added 77.25%
87,365 $393,000
Q1 2022

May 13, 2022

SELL
$8.19 - $13.89 $31,646 - $53,670
-3,864 Reduced 7.27%
49,289 $445,000
Q4 2021

Feb 14, 2022

BUY
$12.98 - $29.75 $41,912 - $96,062
3,229 Added 6.47%
53,153 $729,000
Q3 2021

Nov 15, 2021

SELL
$12.13 - $23.82 $41,727 - $81,940
-3,440 Reduced 6.45%
49,924 $1.12 Million
Q2 2021

Aug 16, 2021

BUY
$8.34 - $14.59 $445,055 - $778,580
53,364 New
53,364 $714,000
Q4 2020

Feb 16, 2021

SELL
$2.48 - $4.64 $244,245 - $456,975
-98,486 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$2.58 - $4.16 $19,765 - $31,869
7,661 Added 8.43%
98,486 $255,000
Q2 2020

Aug 14, 2020

BUY
$2.87 - $4.12 $260,667 - $374,199
90,825 New
90,825 $317,000
Q2 2018

Aug 14, 2018

SELL
$6.29 - $8.22 $84,776 - $110,789
-13,478 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$6.51 - $9.14 $14,608 - $20,510
2,244 Added 19.98%
13,478 $86,000
Q4 2017

Feb 14, 2018

BUY
$7.95 - $11.15 $14,246 - $19,980
1,792 Added 18.98%
11,234 $102,000
Q3 2017

Nov 14, 2017

BUY
$7.74 - $10.78 $73,081 - $101,784
9,442
9,442 $93,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $92.8M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.